Heart Failure Reviews最新文献_第4页

A spotlight on congestion in acute heart failure: a joint session with the Romanian Society of Cardiology (part I). 聚焦于急性心力衰竭中的充血：与罗马尼亚心脏病学会的联合会议（第一部分）。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-04-29 DOI: 10.1007/s10741-025-10515-0

Linda Ye, Alex J Chang, Ovidiu Chioncel, Elena-Laura Antohi, Oliviana Geavlete, Magdy Abdelhamid, Mariana Adamo, Jan Biegus, Vijay Chopra, Gad Cotter, Avishay Grupper, Mitja Lainscak, Alexandre Mebazaa, Alberto Palazzuoli, Giuseppe Rosano, Gianluigi Savarese, Sean P Collins, Steven A Hamilton, Andrew P Ambrosy

{"title":"A spotlight on congestion in acute heart failure: a joint session with the Romanian Society of Cardiology (part I).","authors":"Linda Ye, Alex J Chang, Ovidiu Chioncel, Elena-Laura Antohi, Oliviana Geavlete, Magdy Abdelhamid, Mariana Adamo, Jan Biegus, Vijay Chopra, Gad Cotter, Avishay Grupper, Mitja Lainscak, Alexandre Mebazaa, Alberto Palazzuoli, Giuseppe Rosano, Gianluigi Savarese, Sean P Collins, Steven A Hamilton, Andrew P Ambrosy","doi":"10.1007/s10741-025-10515-0","DOIUrl":"10.1007/s10741-025-10515-0","url":null,"abstract":"Heart failure (HF) is a leading cause of hospitalizations, with over 1 million admissions annually in the USA and Europe due to signs and symptoms of congestion. Congestion in HF is now understood to result from both an absolute increase in total body fluid volume and a relative redistribution of fluid from capacitance vessels to the effective circulation. While guideline-directed medical therapy (GDMT) has greatly improved the outlook for stable HF patients, there has been little progress in managing acute HF (AHF) over the past 50 years. To address this unmet need, a group of expert clinicians met at the 63rd Annual Romanian Society of Cardiology Meeting on September 20th, 2024. They critically evaluated current evidence and identified knowledge gaps in three key areas of AHF management: (1) enhancing diuresis beyond standard therapy; (2) targeting fluid redistribution with intravenous vasodilators; and (3) applying hemodynamic profiling for personalized care. The first part of the discussion centered on enhanced diuresis strategies, covering contemporary real-world practice patterns, the relationship between residual congestion and hospital readmissions, findings from clinical trials of diuretic strategies, and recent insights into the role of GDMT in the acute setting. The panel also highlighted the limitations of existing evidence and proposed a research roadmap to optimize diuretic strategies in conjunction with GDMT in AHF, with the ultimate goal of facilitating decongestion in order to restore euvolemia and improve post-discharge outcomes.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"883-898"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity and inflammation in chronic and acute heart failure. 慢性和急性心力衰竭中的肥胖和炎症。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-03 DOI: 10.1007/s10741-025-10518-x

Gad Cotter, Mark C Petrie, Javed Butler, Beth Davison, Ovidiu Chioncel, Jan Biegus, Matteo Pagnesi, Adriaan A Voors, Marco Metra, Piotr Ponikowski, Douglas Mann, Deepak L Bhatt

引用次数: 0

The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment. 芬烯酮在慢性肾病- 2型糖尿病合并治疗中的作用及其对心力衰竭预防和治疗的意义

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-31 DOI: 10.1007/s10741-025-10520-3

Pam R Taub, Stephen J Greene, Marat Fudim

{"title":"The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment.","authors":"Pam R Taub, Stephen J Greene, Marat Fudim","doi":"10.1007/s10741-025-10520-3","DOIUrl":"10.1007/s10741-025-10520-3","url":null,"abstract":"The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone is indicated in the United States for use in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Results from the FIDELIO-DKD and FIGARO-DKD Phase 3 clinical trials showed a statistically significant reduction in the risk of CKD progression and cardiovascular events with finerenone versus placebo when added to maximally tolerated dose of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. The cardiovascular event risk reduction was primarily driven by the reduction in the risk of hospitalization for heart failure (HF). Recent results from the Phase 3 FINEARTS-HF trial in patients with HF with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) showed a significantly lower rate of a composite of total worsening HF events and death from cardiovascular causes with finerenone versus placebo. Further Phase 3 trials in additional HF populations are ongoing. The steroidal MRAs spironolactone and eplerenone are included in clinical practice guidelines for the treatment of symptomatic HF, but the highest class (grade 1) recommendations are in HF with reduced ejection fraction only. Based on the available evidence, finerenone presents as a new evidence-based therapy for HFpEF/HFmrEF in addition to its current application in CKD associated with T2D. The aim of our review article is to present the current evidence available on the potential kidney and cardioprotective effects of finerenone to inform healthcare professionals (particularly those who work in cardiology).","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"971-984"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SEISMIC-HF 1: key findings from AHA24 and implications for remote cardiac monitoring. SEISMIC-HF 1: AHA24的主要发现及其对远程心脏监测的意义。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-04-23 DOI: 10.1007/s10741-025-10514-1

Baljash Cheema, Anjan Tibrewala

{"title":"SEISMIC-HF 1: key findings from AHA24 and implications for remote cardiac monitoring.","authors":"Baljash Cheema, Anjan Tibrewala","doi":"10.1007/s10741-025-10514-1","DOIUrl":"10.1007/s10741-025-10514-1","url":null,"abstract":"While there is continued progress in developing therapies for patients with heart failure, the condition results in significant morbidity and a sizeable economic impact on our society. Recent advances in wearable sensors combined with machine learning algorithms give hope that heart failure can be better managed remotely and allow for improved clinical outcomes. This is a focused review of the key findings of the SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF 1) study, presented at the American Heart Association's Scientific Sessions 2024 in Chicago, Illinois. This study showcased the ability of a machine learning algorithm to estimate pulmonary capillary wedge pressure in patients with heart failure with reduced ejection fraction, utilizing seismocardiography, photoplethysmography, and electrocardiography signals obtained non-invasively through a wearable sensor patch (CardioTag) for model input. The authors showed a significant correlation between model-predicted pulmonary capillary wedge pressure and the gold standard pressure measurement obtained from right heart catheterization. Future investigations should assess the implementation of this technology as a part of a treatment strategy for outpatient heart failure care and explore its performance in additional study populations including those with heart failure with preserved ejection fraction and in patients outside of the clinical environment.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1099-1101"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of echocardiography in the diagnosis of heart failure with preserved ejection fraction. 超声心动图在保留射血分数的心力衰竭诊断中的作用。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-12 DOI: 10.1007/s10741-025-10516-z

Bharathi Upadhya, Geoffrey A Rose, R Brandon Stacey, Richard A Palma, Thomas Ryan, Akshay Pendyal, Anita M Kelsey

{"title":"The role of echocardiography in the diagnosis of heart failure with preserved ejection fraction.","authors":"Bharathi Upadhya, Geoffrey A Rose, R Brandon Stacey, Richard A Palma, Thomas Ryan, Akshay Pendyal, Anita M Kelsey","doi":"10.1007/s10741-025-10516-z","DOIUrl":"10.1007/s10741-025-10516-z","url":null,"abstract":"Heart failure (HF) with preserved ejection fraction (HFpEF) is the most common form of HF in older adults. While manifest as distinct clinical phenotypes, almost all patients with HFpEF will present with exercise intolerance or exertional dyspnea. Distinguishing HFpEF from other clinical conditions remains challenging, as the accurate diagnosis of HFpEF involves integrating a diverse array of cardiovascular (CV) structural and physiologic inputs. Owing to its intrinsic ability to characterize the structure and function of the myocardium, cardiac valves, pericardium, and vasculature, echocardiography (TTE) has emerged as an essential modality for diagnosing HFpEF. In contrast to HF with reduced EF, however, no single TTE variable defines HFpEF. Abnormal diastolic function is typically associated with HFpEF, but \"diastolic dysfunction\" per se is not synonymous with \"HFpEF\": the pathophysiology of HFpEF is more complex than diastolic dysfunction alone. HFpEF may involve abnormalities at multiple loci within the CV system, including (1) dysfunction of the left ventricle, left atrium, or right ventricle; (2) pulmonary hypertension or pulmonary vascular disease; (3) pericardial restraint; (4) abnormal systemic vascular impedance; (5) coronary or peripheral microcirculatory dysfunction; and (6) defects of tissue oxygen uptake within the periphery. Thus, the accurate diagnosis of HFpEF - and its specific clinical phenotypes - requires diagnostic algorithms that comprise multiple clinical variables, many of which may be derived from TTE data. Refining such algorithms to better discriminate among specific HFpEF phenotypes is the subject of continued investigation.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"899-922"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outpatient worsening heart failure: innovative decongestion strategies and health equity implications. 门诊恶化心力衰竭：创新的去充血策略和健康公平的影响。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-04-05 DOI: 10.1007/s10741-025-10509-y

Rami Halaseh, Grace K Sun, Ankeet S Bhatt, Alex J Chang, Jana Svetlichnaya, Sirtaz Adatya, Marat Fudim, Stephen J Greene, Daniel R Bensimhon, Eric D Adler, Tamas Alexy, Jan Biegus, Andrew J Sauer, Peter S Pang, Sean P Collins, Ambarish Pandey, Javed Butler, Andrew P Ambrosy

{"title":"Outpatient worsening heart failure: innovative decongestion strategies and health equity implications.","authors":"Rami Halaseh, Grace K Sun, Ankeet S Bhatt, Alex J Chang, Jana Svetlichnaya, Sirtaz Adatya, Marat Fudim, Stephen J Greene, Daniel R Bensimhon, Eric D Adler, Tamas Alexy, Jan Biegus, Andrew J Sauer, Peter S Pang, Sean P Collins, Ambarish Pandey, Javed Butler, Andrew P Ambrosy","doi":"10.1007/s10741-025-10509-y","DOIUrl":"10.1007/s10741-025-10509-y","url":null,"abstract":"Worsening heart failure (WHF) is a major clinical and economic challenge, contributing to high rates of hospitalization and significant healthcare costs. While WHF has traditionally been managed through hospitalization, recent approaches are shifting toward outpatient care to maximize patient time spent at home and optimize allocation of hospital resources. Emerging treatments like subcutaneous furosemide and intranasal bumetanide offer promising alternatives for safe, well-tolerated, and effective diuresis outside the hospital. However, these novel strategies face several challenges, including the need for clinician/staff training, patient education, logistical difficulties, and a lack of evidence in diverse populations. To ensure equitable management, it is also essential to address healthcare disparities, particularly in socioeconomically disadvantaged and rural populations. While these new treatments have the potential to improve care delivery, additional research is necessary to assess their comparative effectiveness and overcome current limitations fully.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"831-841"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex differences in the presentation, pathophysiology, and prognosis of heart failure with preserved ejection fraction. 保留射血分数的心力衰竭的表现、病理生理和预后的性别差异。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-30 DOI: 10.1007/s10741-025-10528-9

Imo A Ebong, Ahmad Gill, Duke Appiah, Rina Mauricio

{"title":"Sex differences in the presentation, pathophysiology, and prognosis of heart failure with preserved ejection fraction.","authors":"Imo A Ebong, Ahmad Gill, Duke Appiah, Rina Mauricio","doi":"10.1007/s10741-025-10528-9","DOIUrl":"10.1007/s10741-025-10528-9","url":null,"abstract":"The prevalence of HFpEF is rising, especially among older females. Females possess unique attributes in their cardiovascular risk factor profiles, cardiac remodeling patterns, and sex hormonal composition that predispose them to an increased risk of developing HFpEF in comparison to males. Although comorbidities play an important role in driving the cardiac and extracardiac abnormalities manifested in HFpEF, there are ventricular-vascular properties that cannot be explained by comorbidities alone. The \"hypertension, arterial stiffness and cardiac remodeling\" and \"obesity, chronic inflammation and microvascular dysfunction\" phenotypic profiles represent two pathophysiological mechanistic pathways that are predominant in the HFpEF syndrome among females. While females exhibit worse symptoms and signs of congestion as well as poorer quality of life, they generally have better clinical outcomes in comparison to males. In this review, we will discuss the available evidence on the sex differences that exist in HFpEF including its pathophysiology, clinical presentation, and outcomes, while concurrently highlighting gaps in the existing literature. We will also mention features of HFpEF that are common to both sexes.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1045-1059"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart failure with preserved ejection fraction therapeutics: in search of the pillars. 保留射血分数治疗心力衰竭：寻找支柱。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-22 DOI: 10.1007/s10741-025-10524-z

Abdelghani El Rafei, Josephine A Harrington, Caio A M Tavares, Patrícia O Guimarães, Andrew P Ambrosy, Marc P Bonaca, Andrew J Sauer, Orly Vardeny, Mario Enrico Canonico

{"title":"Heart failure with preserved ejection fraction therapeutics: in search of the pillars.","authors":"Abdelghani El Rafei, Josephine A Harrington, Caio A M Tavares, Patrícia O Guimarães, Andrew P Ambrosy, Marc P Bonaca, Andrew J Sauer, Orly Vardeny, Mario Enrico Canonico","doi":"10.1007/s10741-025-10524-z","DOIUrl":"10.1007/s10741-025-10524-z","url":null,"abstract":"Heart failure (HF) affects nearly 8 million individuals in the USA, with approximately half diagnosed with heart failure with preserved ejection fraction (HFpEF). HFpEF is associated with high morbidity and mortality, with fewer than 25% of patients surviving beyond 5 years after diagnosis. Historically, poor outcomes have been largely attributed to a lack of effective disease-modifying therapies. However, the past 5 years have marked a transformative era in HFpEF management, with multiple landmark clinical trials demonstrating benefits for novel therapeutic classes. These include sodium-glucose cotransporter 2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (Ns-MRAs), and glucagon-like peptide-1 (GLP-1) receptor agonists, particularly for the obesity-related HFpEF phenotype. In this review, we summarize the evolution of HFpEF therapeutics, from traditional heart failure treatments with limited efficacy to emerging targeted therapies, highlighting the latest evidence shaping a modern, comprehensive approach to HFpEF management.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1005-1014"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Emerging use of pulmonary artery and cardiac pressure sensing technology in the management of worsening heart failure events. 更正：肺动脉和心脏压力传感技术在恶化心力衰竭事件管理中的应用。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-06-03 DOI: 10.1007/s10741-025-10534-x

Matthew I Mace, Anuradha Lala, Timothy J Fendler, Andrew J Sauer

引用次数: 0

Urea, TMAO, betaine and other osmolytes as endogenous diuretics in heart failure and hypertension. 尿素、氧化三甲胺、甜菜碱等渗透液在心力衰竭和高血压中的内源性利尿剂作用。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-06-02 DOI: 10.1007/s10741-025-10530-1

Izabella Mogilnicka, Wojciech Kopacz, Kinga Jaworska, Zainab Alramadhan, Marcin Ufnal

{"title":"Urea, TMAO, betaine and other osmolytes as endogenous diuretics in heart failure and hypertension.","authors":"Izabella Mogilnicka, Wojciech Kopacz, Kinga Jaworska, Zainab Alramadhan, Marcin Ufnal","doi":"10.1007/s10741-025-10530-1","DOIUrl":"10.1007/s10741-025-10530-1","url":null,"abstract":"Diuretics are essential for managing fluid overload in heart failure (HF) and controlling blood pressure in hypertension. However, their use is often associated with complications such as electrolyte imbalances and neurohormonal dysregulation, which can limit their effectiveness and contribute to adverse outcomes. These challenges underscore the need for alternative or adjunctive strategies to better manage fluid retention and congestion. Osmolytes are small molecules that help counteract increases in extracellular osmotic and hydrostatic pressure and are naturally present at high concentrations in the renal medulla. Notably, elevated serum levels of osmolytes such as trimethylamine N-oxide (TMAO) and betaine have been observed in patients with HF, although their role in the pathophysiology of the disease remains unclear. Given the known diuretic properties of osmolytes such as urea-historically used in the management of HF-it is plausible that other osmolytes may similarly modulate diuresis and volume status. This review examines the biological actions of several key osmolytes, including urea, TMAO, betaine, and taurine. Emerging evidence supports the need for further preclinical and clinical studies to investigate the potential diuretic and cytoprotective effects of TMAO, betaine, and taurine in the prevention and treatment of HF and hypertension.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1061-1074"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0